Harvard Medical School (HMS and HSDM)
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Harvard Medical School (HMS and HSDM) sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Harvard Medical School (HMS and HSDM): 26 sponsored US clinical trials, 4 recruiting.
Harvard Medical School (HMS and HSDM) sponsors 26 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 14 completed. 4 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Implant Complication, with 2 trials.
Top-decile sponsor footprint
Harvard Medical School (HMS and HSDM) ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT
NCT07440303
Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease
NCT06602544
The Effect of Work Requirements in SNAP in Virginia
NCT04888832
Vertical Soft Tissue Augmentation With CTG vs ADM
NCT05729607
Efficacy of a Dental Implant System for Immediate Restoration
NCT06651502
Buccal Graft + Collagen Matrix Versus Free Gingival Graft for Keratinized Mucosa Augmentation at Implant Sites
NCT05844475
Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences
NCT05576922
Effect of Cash Benefits on Health Care Spending
NCT07381049
Cash Benefits and Reproductive/Perinatal Health
NCT05782660
AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment
NCT07203885
Additively Versus Subtractively Manufactured Implant Supported Fixed Dental Prostheses
NCT07090863
The Effect of Community Building Through Virtual, Team-Based Exercise on Burnout
NCT05194410
Effect of Using Placental Membranes on Healing and Post-op Pain After Gum Surgery
NCT04957342
Effect of Cash Benefits on Health Care Utilization
NCT05622903
Racial Inequality in Inhaler Fills for COPD - A Trial of Reduced Cost-Sharing
NCT05497999
Task-based Credentialing for Medical Officers in Spinal Anesthesia
NCT04438811
Rt-fMRI Neurofeedback and AH in Schizophrenia
NCT03504579
Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Sinus Floor Elevation
NCT02404649
Community Partnership to Examine Racial and Ethnic Differences in Health Care for Hypertension and Diabetes
NCT00379652
Computerized and Mailed Reminders in Increasing the Rate of Colorectal Cancer Screening in Adults With an Average Risk for Colorectal Cancer
NCT00355004
Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp
NCT00397969
Outreach and Treatment for Depression in the Labor Force
NCT00057590
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169065
Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00169091
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169039
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
NCT00320632
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 4 |
Therapeutic Areas
Where Harvard Medical School (HMS and HSDM) enrollment is open (later-stage tilt)
4 recruiting of 26 indexed (15% open); 14 completed (54%).
Phase mix: 4 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Implant Complication (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Harvard Medical School (HMS and HSDM): open-pipeline peers nationwide
Peers matched on 26 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Harvard Medical School (HMS and HSDM) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- Aldeyra Therapeutics · 26 trials · 4% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
- Candel Therapeutics · 15% recruiting · 13 trials
Related
What to do with this Harvard Medical School (HMS and HSDM) page
26 registered trials is a research-attention snapshot, not an endorsement of Harvard Medical School (HMS and HSDM) or any single study.
- 4 of Harvard Medical School (HMS and HSDM)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Implant Complication is the condition Harvard Medical School (HMS and HSDM) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Implant Complication trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Harvard Medical School (HMS and HSDM) pipeline card: 26 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.